What is it about?
Cisplatin-based concurrent chemoradiation (CRT) is the only treatment option to date for target killing of cervical cancer cells. However, the response of patients undergoing CRT shows widespread toxicities that may be either early or late in the therapy which is a current clinical challenge. In the present study analyzed is there any correlation between HPV infection and treatment outcome of CRT in CaCx patients?
Featured Image
Why is it important?
Regular screening for HPV and early detection of cervical cancer through Pap tests and HPV DNA tests are crucial for identifying and managing the disease at its early stages. Vaccination against HPV is also an effective preventive measure, as it can protect against most of the common HPV types associated with CaCx. It is important to consult a healthcare professional for personalized information and guidance regarding HPV infection, cervical cancer, and the appropriate treatment options based on individual circumstances.
Perspectives
The tremendous unpredictability of adverse reactions (toxicities) and treatment efficacy among CaCx patients are a significant challenge for clinicians. Moreover, little is known about the correlation of HPV infection with the treatment response of CRT in CaCx patients. Therefore, it is required to identify the risk factors affecting the treatment response and potential approaches for tackling such issues. I hope this article helps clinicians to tailor treatment regimens based on HPV infection and take care of other studied co-risk factors.
Atar Singh Kushwah
Icahn School of Medicine at Mount Sinai
Read the Original
This page is a summary of: Impact of Human Papillomavirus (HPV) Infection on the Treatment Outcome
of Concomitant Chemoradiotherapy (CRT) in Cervical Cancer, Current Cancer Therapy Reviews, May 2024, Bentham Science Publishers,
DOI: 10.2174/1573394719666230807161948.
You can read the full text:
Contributors
The following have contributed to this page
